Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Senti Biosciences, Inc. - Common Stock (NQ: SNTI )

7.013 -0.127 (-1.77%)
Streaming Delayed Price Updated: 1:31 PM EST, Dec 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Senti Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
AT&T To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
US Stock Futures Dip As Dollar Slides And Treasuries Rise After S&P Hits 54th All-Time High This Year: Analyst Sees 'Further Upside' Of Around 10% In 2025 From Current Levels
U.S. stock futures were in negative territory during Tuesday’s premarket hours as the dollar slipped to 106.3 level. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
SNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024
Senti Biosciences just reported results for the second quarter of 2024. 
Via InvestorPlace
SNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024
Senti Biosciences just reported results for the first quarter of 2024. 
Via InvestorPlace
Why Is Senti Biosciences Stock Surging Over 400% On Monday?
Senti Biosciences shares surge as SENTI-202 trial shows promise in AML patients; company secures $37.6M in private equity funding. 
Via Benzinga
Nasdaq Gains Over 100 Points; Li Auto Delivers 48,740 Vehicles In November
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024 
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth diving into this morning as we break down all of the biggest news moving shares on Tuesday! 
Via InvestorPlace
Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
Penny stocks are risky, but follow the money to find winners. Stocks with significant volume spikes may have what it takes for higher share prices. 
Via MarketBeat
Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?
Senti Biosciences shares are trading higher by 102.6% during Monday's session. The company was awarded $8 million from the California Institute for Regenerative Medicines. 
Via Benzinga
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia 
From Senti Biosciences, Inc.
Via GlobeNewswire
Why Is Beyond Air (XAIR) Stock Down 22% Today?
Beyond Air stock is down on Tuesday as investors in XAIR react to the company mixed earnings report for the first quarter of the year. 
Via InvestorPlace
Why Is Faraday Future (FFIE) Stock Down 27% Today?
Faraday Future stock is down on Tuesday after the troubled EV company announced plans for a reverse split of FFIE shares. 
Via InvestorPlace
Why Is Senti Biosciences (SNTI) Stock Up 32% Today?
Senti Biosciences stock is up on Tuesday with heavy pre-market trading of SNTI shares despite a lack of news from the company. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
From Senti Biosciences, Inc.
Via GlobeNewswire
SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023
SNTI stock results show that Senti Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?
Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.